CytomX Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.8% | -8.5% | -13.8% | -12.7% | -13.3% | -18.3% | +77.7% | -9.6% | -4.2% | +137.1% | +6.1% | |
| – | -9.1% | -8.6% | -14.4% | -13.2% | -13.6% | -19.3% | +90.0% | -9.4% | -3.5% | +145.3% | +5.7% | |
| – | -34.0% | +110.7% | +19.5% | -6.2% | -6.2% | +25.1% | +3.0% | -30.3% | -62.9% | +127.6% | -40.3% | |
| – | -10.1% | -13.9% | -8.7% | -14.3% | -14.4% | -20.6% | +97.9% | -9.1% | -4.6% | +153.0% | -4.7% | |
| – | +41.9% | +283.9% | -78.9% | +20.8% | -7.4% | -37.0% | -4.4% | -12.8% | +23.6% | -67.9% | +5,704.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -4.8% | -4.9% | -5.3% | -5.5% | -6.0% | -6.2% | -6.8% | -7.1% | -7.6% | -8.4% | -9.0% | |
| – | -8.5% | -13.2% | -12.0% | -14.7% | -25.5% | -39.3% | -24.9% | -7.8% | +3.3% | -25.0% | +100.8% | |
| – | +6.2% | -7.3% | -1.2% | -16.5% | -28.1% | -41.5% | -21.9% | +4.6% | +13.6% | -27.0% | +17.2% | |
| – | +2.9% | +2.9% | +2.9% | +2.9% | +2.9% | +2.9% | +2.8% | +2.8% | -24.2% | -32.6% | -47.6% | |
| – | -14.5% | +34.7% | -68.9% | +132.7% | -23.5% | -74.6% | -17.8% | +184.6% | +101.4% | +5.1% | +41.7% | |
| – | – | – | – | – | – | – | +378.7% | -10.4% | -7.8% | +223.1% | -5.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -16.9% | +22.8% | +2.7% | +0.4% | -6.0% | +8.8% | +48.1% | +27.8% | +3.1% | +4.2% | +23.5% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.